ModiQuest's NET-targeted antibody spinoff closed a $20.9m round that also featured BrightGene, both having contributed to the first close last year.
Netherlands-based antibody therapeutics developer Citryll completed an €18.5m ($20.9m) series A round yesterday featuring antibody developer ModiQuest and pharmaceutical company BrightGene.
The round was co-led by healthcare-focused venture capital firms BioGeneration Ventures and Seventure Partners, the latter through its Health for Life Capital II fund. It included state-backed VC fund BOM Brabant Ventures.
Founded by in 2015 ModiQuest, Citryll is advancing antibodies to inhibit neutrophil extracellular traps (NETs), extracellular fibres that can contribute to conditions such as asthma, thrombosis and…